Evidence map›Paper›PMID 40908304›Full record

ReviewNature reviews. Nephrology2025

Long COVID and the kidney.

Vanja Ivković, Urmila Anandh, Samira Bell, Andreas Kronbichler, Maria Jose Soler, Annette Bruchfeld

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vanja IvkovićDepartment of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden. vanja.ivkovic@gmail.com.
Urmila AnandhDepartment of Nephrology, Amrita Institute of Medical Sciences, New Delhi, India.ORCID 0000-0003-3298-8642
Samira BellDivision of Population Health and Genomics, University of Dundee, Dundee, UK.ORCID 0000-0001-9100-1575
Andreas KronbichlerDepartment of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.ORCID 0000-0002-2945-2946
Maria Jose SolerNephrology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0003-3621-0766
Annette BruchfeldDepartment of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden. annette.bruchfeld@liu.se.ORCID 0000-0002-9752-9941

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long coronavirus disease (COVID) - commonly defined as symptoms and/or long-term effects that persist for at least 3 months after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cannot be explained by an alternative diagnosis - is a complex, multifaceted and heterogeneous disease that affects many organ systems, including the kidney. COVID-19 can cause acute kidney injury, and several studies have reported an increased risk of chronic kidney disease (CKD) following COVID-19, suggesting that CKD can be a manifestation of long COVID. Furthermore, patients with CKD are at an increased risk of severe COVID-19 and of long COVID. COVID-19 has also been associated with the development of COVID-19-associated nephropathy, which is a collapsing form of focal segmental glomerulosclerosis, and an increased incidence of new-onset vasculitis. Some early reports described associations of COVID-19 and/or SARS-CoV-2 vaccines with relapse or new-onset of other glomerular diseases, but this link was not confirmed in large population-based studies. SARS-CoV-2 vaccination reduces the risk of COVID-19 and long COVID and is particularly important for protecting vulnerable populations such as patients with CKD. Structured long-term follow-up of patients with COVID-19 and post-infectious sequelae is needed to provide further insight into the trajectory of long COVID and enable identification of those at risk of CKD.

Indexed as

COVID-19Renal Insufficiency, ChronicCOVID-19 VaccinesHumansPost-Acute COVID-19 SyndromeSARS-CoV-2COVID-19 Vaccines

Identifiers

PMID40908304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.